Skip to content

Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans

Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04218799
Enrollment
19
Registered
2020-01-06
Start date
2014-08-12
Completion date
2015-09-22
Last updated
2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Microbiome

Keywords

intranasal mupirocin, topical chlorhexidine

Brief summary

The purpose of the research is to find out the effect of commonly used topical antibiotics on the bacteria that live in the nose, throat and on the skin of older adults. In addition, the investigators want to determine if these topical antibiotics affect how bacteria are spread in Community Living Centers of the VA Maryland Health Care System.

Interventions

DRUGIntranasal Mupirocin and Topical Chlorhexidine

Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.

Sponsors

VA Office of Research and Development
CollaboratorFED
University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 50 years or older. * Living in a participating nursing home for at least 80% of the past 3 months- * Willing to provide anterior nares, posterior pharynx, skin and throat specimens over the study period. * Willing to use intranasal mupirocin and topical chlorhexidine over a five day period. * Provide signed and dated informed consent from subject or LAR.

Exclusion criteria

* Recent history of MRSA colonization * Use of mupirocin nasal ointment in past 3 months * Use of topical chlorhexidine in past 3 months * History of an allergic reaction to chlorhexidine or mupirocin

Design outcomes

Primary

MeasureTime frameDescription
Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization8 weeksChange in the abundance of Staphylococcus aureus in the nose from immediately before mupirocin administration to 8 weeks after mupirocin administration.
Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization8 weeksChange in the abundance of Staphylococcus aureus in the throat from immediately before mupirocin administration to 8 weeks after mupirocin administration.
Change in the Abundance of Gram Negative Bacteria on the Subclavian Skin After Decolonization12 monthsQuantitative PCR using 16s rRNA is used to quantify the total bacterial load of Gram negative bacteria on the subclavian skin before and after decolonization.
Change in the Abundance of Gram Negative Bacteria on the Femoral Skin After Decolonization12 monthsQuantitative PCR using 16s rRNA is used to quantify the total bacterial load of Gram negative bacteria on the femoral skin before and after decolonization.

Countries

United States

Participant flow

Pre-assignment details

11 participants were S. aureus negative in the nose at enrollment and were withdrawn from the study as the use of mupirocin was not clinically indicated. 1 participant was discharged from the nursing home prior to receiving mupirocin.

Participants by arm

ArmCount
Intranasal Mupirocin and Topical Chlorhexidine
Intranasal Mupirocin and Topical Chlorhexidine: Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
7
Total7

Baseline characteristics

CharacteristicIntranasal Mupirocin and Topical Chlorhexidine
Age, Continuous71.0 years
STANDARD_DEVIATION 14.4
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
5 Participants
Region of Enrollment
United States
7 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 7
serious
Total, serious adverse events
0 / 7

Outcome results

Primary

Change in the Abundance of Gram Negative Bacteria on the Femoral Skin After Decolonization

Quantitative PCR using 16s rRNA is used to quantify the total bacterial load of Gram negative bacteria on the femoral skin before and after decolonization.

Time frame: 12 months

Population: Femoral skin samples deteriorated prior to sample analysis and cannot be used.

Primary

Change in the Abundance of Gram Negative Bacteria on the Subclavian Skin After Decolonization

Quantitative PCR using 16s rRNA is used to quantify the total bacterial load of Gram negative bacteria on the subclavian skin before and after decolonization.

Time frame: 12 months

Population: Subclavian skin samples deteriorated prior to sample analysis and cannot be used.

Primary

Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization

Change in the abundance of Staphylococcus aureus in the nose from immediately before mupirocin administration to 8 weeks after mupirocin administration.

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
Intranasal Mupirocin and Topical ChlorhexidineChange in the Abundance of Staphylococcus Aureus in the Nose After Decolonization-4174 fg/uLStandard Deviation 11003
Primary

Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization

Change in the abundance of Staphylococcus aureus in the throat from immediately before mupirocin administration to 8 weeks after mupirocin administration.

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
Intranasal Mupirocin and Topical ChlorhexidineChange in the Abundance of Staphylococcus Aureus in the Throat After Decolonization-3395 fg/uLStandard Deviation 8954

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026